Dodev T S, Bowen H, Shamji M H, Bax H J, Beavil A J, McDonnell J M, Durham S R, Sutton B J, Gould H J, James L K
Randall Division of Cell and Molecular Biophysics, King's College London, London, UK.
MRC and Asthma UK Centre for Allergic Mechanisms of Asthma, King's College London, London, UK.
Allergy. 2015 Jun;70(6):720-4. doi: 10.1111/all.12607. Epub 2015 Mar 28.
IgG4 purified from patients undergoing specific allergen immunotherapy inhibits the activities of the serum IgE in in vitro assays and is thought to reduce the symptoms of the disease. However, it is not known whether this is related to an intrinsic property of this subclass or only the allergen specificity. We tested the hypothesis that allergen specificity is the critical determinant for this activity using a panel of antibodies with identical specificity but different subclasses. The different antibodies were all able to inhibit the activity of IgE to the same extent. We demonstrate that specificity is the dominant factor determining the ability of an antibody to block allergen-dependent IgE activity.
从接受特异性变应原免疫疗法的患者体内纯化出的IgG4，在体外试验中可抑制血清IgE的活性，并被认为能减轻疾病症状。然而，尚不清楚这是与该亚类的内在特性有关，还是仅与变应原特异性有关。我们使用一组具有相同特异性但不同亚类的抗体，检验了变应原特异性是这种活性的关键决定因素这一假说。不同的抗体均能在相同程度上抑制IgE的活性。我们证明，特异性是决定抗体阻断变应原依赖性IgE活性能力的主导因素。
